publication venue for
- Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus-Driven Cancers.. 28:4479-4493. 2022
- Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma.. 27:5528-5535. 2021
- Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs.. 27:3005-3016. 2021
- CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols.. 24:4976-4987. 2018
- Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?. 23:3263-3268. 2017
- Targeting fibroblast growth factor pathways in prostate cancer.. 19:5856-5866. 2013
- Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.. 18:6758-6770. 2012
- Abstract A38: Whole methylome explorations of paired lung tumor and non-tumor clinical samples. 18:a38-a38. 2012
- Longitudinal investigation of permeability and distribution of macromolecules in mouse malignant transformation using PET.. 17:550-559. 2011
- Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2.. 15:6780-6789. 2009
- Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer.. 15:543-552. 2009
- Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.. 14:6387-6395. 2008
- 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce apoptosis and inhibit renal cell carcinoma growth.. 13:6743-6752. 2007
- Quantification of the heterogeneity in breast cancer cell lines using whole-cell impedance spectroscopy.. 13:139-143. 2007
- Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium.. 12:6373-6378. 2006
- Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.. 12:6209s-6212s. 2006
- Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.. 12:6213s-6216s. 2006
- Genomics and proteomics of bone cancer.. 12:6217s-6221s. 2006
- Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.. 12:2178-2184. 2006
- Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer.. 11:8258-8264. 2005
- Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis.. 7:818-823. 2001
- Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice.. 2:511-520. 1996
- Abstract A6: The ES-2 ovarian cancer causes muscle wasting in vitro and in vivo: A novel experimental model of cancer cachexia. 19:a6-a6.
- Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma.. 21:1741-1751.
- Abstract A52: Serially passaging ovarian cancer spheroids as an in situ model for emergence of chemoresistance and enrichment of cancer stem cells 2020
- Abstract A33: Patient-specific evaluation of chemoresistance and tumor recurrence using ovarian cancer stem cell spheroids 2018
- Abstract AP22: CHEMORESISTANCE, TUMOR INITIATION AND TUMOR REEMERGENCE TRENDS IN MALIGNANT ASCITESDERIVED OVARIAN CANCER STEM CELL SPHEROIDS 2017
- Abstract DPOC-012: THERANOSTIC NANOPLATFORM FOR IMAGEGUIDED SURGERY AND INTRAOPERATIVE PHOTOTHERAPY FOR OVARIAN CANCER TREATMENT 2017
- Activation of Putative Compensatory Pathways upon Deletion of Erbb3 in Mutant EGFR-driven Lung Cancer 2012
- Anticancer activity of DRF7295: A peptide combination targeting multiple neuropeptide receptors in gastrointestinal cancers. 2005
- DRF7295: A novel peptide based signal transcluction modulator for the treatment of gastrointestinal carcinomas. 2005